Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy
Authors:
- Carlo PutzuCPCarlo Putzu
- Riccardo SerraRSRiccardo Serra
- Rachele CampusRCRachele Campus
- Giovanni Maria FaddaGFGiovanni Maria Fadda
- Claudio SiniCSClaudio Sini
- Andrea MarongiuAMAndrea Marongiu
- Giorgio Carlo GinesuGGGiorgio Carlo Ginesu
- Alessandro Giuseppe FoisAlessandro Giuseppe Fois
- Giuseppe PalmieriGiuseppe Palmieri
- Angelo ZinelluAZAngelo Zinellu
- Antonio CossuACAntonio Cossu
- Panagiotis PaliogiannisPanagiotis Paliogiannis
Open Access
- 26 August 2024
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 31 (9) , 4955-4967
Abstract
Background: The aim of the study was to investigate a series of complete blood cell count-based biomarkers of systemic inflammation as predictors of clinical outcomes in patients who underwent first-line chemoimmunotherapy for advanced NSCLC. Methods: Consecutive patients with pathologically diagnosed stage III/IV NSCLC and PD-L1 < 50% who underwent first-line chemoimmunotherapy were retrospectively enrolled. The clinical outcomes used for biomarker evaluation were Objective Response Rate (ORR) and Overall Survival (OS). Results: Non-responders had significantly higher values of neutrophil to lymphocyte ratio (NLR, median: 5.36; IQR: 2.78–10.82 vs. 3.31; IQR: 2.15–4.12, p = 0.019), neutrophil to monocyte ratio (NMR, median: 14.00; IQR: 8.82–21.20 vs. 9.20; IQR: 7.45–11.20, p = 0.013), and systemic inflammation index (SII, median: 1395; IQR: 929–3334 vs. 945; IQR: 552–1373, p = 0.025), but only NLR and NMR remained independently associated with clinical response in multivariate logistic regression. In the univariate analysis, white blood cells (OR:1.2202; 95% CI: 1.0339–1.4400, p = 0.019), neutrophils (OR:1.2916; 95% CI: 1.0692–1.5604, p = 0.008), NLR (OR:1.3601: 95% CI: 1.0949–1.6896, p = 0.005) and NMR (OR:1.2159; 95% CI: 1.00396–1.4221, p = 0.015) were significantly associated with survival; Cox regression models confirmed that neutrophils, NLR, and MLR were independently associated with survival; NLR, at a cut-off value of 4.0, showed the better AUC (0.749) in predicting OS. Conclusions: Baseline complete blood cell count biomarkers, especially the NLR, can predict clinical outcomes in patients with advanced NSCLC treated with first-line chemoimmunotherapy.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Diagnostic value of the neutrophil lymphocyte ratio in discrimination between tuberculosis and bacterial community acquired pneumonia: A meta-analysisJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2023
- First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1International Journal of Clinical Oncology, 2023
- Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center studyCancer Immunology, Immunotherapy, 2022
- First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year updateESMO Open, 2021
- Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancerESMO Open, 2021
- Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with NivolumabCancer Immunology, Immunotherapy, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Predictive biomarkers for checkpoint inhibitor-based immunotherapyThe Lancet Oncology, 2016
- VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesisEuropean Journal of Cancer, 2008